Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avation loss narrows; Franchise Brands profit rises

Thu, 03rd Mar 2022 19:32

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Avation PLC - Singapore-based commercial passenger aircraft leasing company - For the six months ended December 31, pretax loss narrows to USD15.9 million from USD60.5 million, due to a much lower impairment loss on aircraft and credit losses. Revenue drops 6% year-on-year to USD57.9 million from USD61.3 million. Avation's aircraft fleet stands at 42, however fleet assets declines 7.0% year-on-year to USD1.00 billion as at December 31 from USD1.08 billion at the end of June.

----------

Franchise Brands PLC - Manchester-based owner of ChipsAway, Willow Pumps and Metro Rod brands - For 2021, pretax profit rises 57% year-on-year to GBP5.8 million from GBP3.7 million the year before, on revenue which grows 17% year-on-year to GBP57.7 million from GBP49.3 million, with double digit sales from Metro Rod and Metro Plumb, as well as a strong recovery from the B2C division. Declares final dividend of 0.9 pence per share, bringing total payout to 1.5p, up 36% from 1.1p. Looking ahead, reports strong start to 2022, with continued sales growth in B2B.

----------

Poolbeg Pharma PLC - London-based pharmaceutical company - For the period from incorporation on March 19 to December 31, posts pretax loss of GBP2.3 million and no revenue as the company continues to develop its severe influenza treatment POLB 001.

----------

Crystal Amber Fund Ltd - Guernsey-based investment company - As at December 31, net asset value per share increases 11% year-on-year to 143.19 pence from 128.99p. For the six month period, delivered NAV negative return of 0.8%, compared to a 4.7% positive return from the Numis Small Cap Index.

----------

JPMorgan Global Growth & Income PLC - invests in companies around the world - As at December 31, net asset value per share increases 6.1% year-on-year to 459.1 pence from 432.3p, while for the six month period, NAV total return is 8.2%, compared to a 7.7% return from the MSCI AC World Index.

----------

t42 IoT Tracking Solutions PLC - Jersey-based provider of tracking, security and monitoring solutions for containers and freight - For 2021, operating loss widens to USD2.7 million from USD1.8 million, on revenue which declines 16% year-on-year to USD4.2 million from USD5.0 million due to supply chain issues and a performance turnaround only taking place near the end of 2021.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - For the six months ended December 31, pretax profit drops 54% to GBP7.3 million from GBP15.8 million a year before, due to a rise in costs and a 10% year-on-year decline in revenue to GBP48.7 million from GBP54.0 million, due to the strategic streamlining of older products. Looking ahead, company has a strong outlook for the full financial year with operating profit on track to meet consensus expectations.

----------

Power Metal Resources PLC - London-based metals exploration company focused in North America, Africa and Australia - For the year ended September 30, pretax loss narrows to GBP623,000 from GBP1.4 million the year before, due to smaller impairment charges, and a slight rise in revenue to GBP37,000 from GBP9,000

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
23 Sep 2021 11:48

EARNINGS UPDATES: Harbour Energy enters black; Fonix profit rises

EARNINGS UPDATES: Harbour Energy enters black; Fonix profit rises

Read more
13 Sep 2021 20:25

IN BRIEF: Allergy Therapeutics cheers secondary endpoint results

IN BRIEF: Allergy Therapeutics cheers secondary endpoint results

Read more
3 Aug 2021 14:33

IN BRIEF: Allergy Therapeutics study confirms peanut vaccine potential

IN BRIEF: Allergy Therapeutics study confirms peanut vaccine potential

Read more
3 Aug 2021 13:43

Allergy Therapeutics upbeat on ex-vivo study of peanut allergy vaccine

(Sharecast News) - Pharmaceutical biotechnology company Allergy Therapeutics announced positive primary results from an ex-vivo biomarker study on Tuesday, evaluating its novel virus-like particle (VLP)-based peanut allergy vaccine candidate, VLP Peanut.

Read more
14 Jul 2021 12:29

Allergy Therapeutics expects revenue rise in year despite challenges

Allergy Therapeutics expects revenue rise in year despite challenges

Read more
24 Jun 2021 19:56

TRADING UPDATES: Vitec and Allergy Therapeutics lift full-year outlook

TRADING UPDATES: Vitec and Allergy Therapeutics lift full-year outlook

Read more
24 Jun 2021 08:07

Allergy Therapeutics FY profits seen 'well ahead' of expectations

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said on Thursday that full-year operating profits were expected to be "well ahead" of market expectations thanks to "significantly lower" expenses.

Read more
6 May 2021 19:25

TRADING UPDATES: Superdry optimistic; Virgin Wines toasts demand surge

TRADING UPDATES: Superdry optimistic; Virgin Wines toasts demand surge

Read more
6 May 2021 15:34

Allergy Therapeutics completes treatment in G309 field study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the completion of the treatment of all patients in its 'G309' exploratory field study to evaluate the efficacy and safety of Grass MATA MPL in subjects with seasonal allergic rhinitis or rhinoconjunctivitis, induced by grass pollen.

Read more
3 Mar 2021 19:14

TRADING UPDATES: Capita sells Irish unit; Daily Mail buys science mag

TRADING UPDATES: Capita sells Irish unit; Daily Mail buys science mag

Read more
3 Mar 2021 13:23

Allergy Therapeutics reports record pre-R&D operating profit

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics reported a 7% improvement in its revenue in actual terms in its interim results on Wednesday, and 5% growth at constant rate, to £54.0m.

Read more
13 Jan 2021 13:29

IN BRIEF: Allergy Therapeutics Hails Growth; Non-Exec Smith To Leave

IN BRIEF: Allergy Therapeutics Hails Growth; Non-Exec Smith To Leave

Read more
5 Jan 2021 18:01

IN BRIEF: Allergy Therapeutics And Imperial Start Peanut Allergy Study

IN BRIEF: Allergy Therapeutics And Imperial Start Peanut Allergy Study

Read more
5 Jan 2021 16:44

Allergy Therapeutics begins peanut allergy vaccine study

(Sharecast News) - Speciality allergy-focussed pharmaceutical company Allergy Therapeutics announced on Tuesday that an ex-vivo biomarker study of blood samples from peanut allergy patients had started at Imperial College London.

Read more
8 Dec 2020 21:07

IN BRIEF: Allergy Therapeutics Shareholders Revolt At General Meeting

IN BRIEF: Allergy Therapeutics Shareholders Revolt At General Meeting

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.